In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.
Sandra Kane-Gill, PharmD, MS
Advertisement
Sandra L. Kane-Gill, PharmD, MS, is a professor of pharmacy and therapeutics and associate dean of faculty affairs at the University of Pittsburgh School of Pharmacy.
Articles by Sandra Kane-Gill, PharmD, MS
In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
5